Company news

Resverlogix Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Resverlogix Appoints A. Brad Cann as Chief Financial Officer

October 13, 2009

TSX Delisting Review - Resverlogix Corp. (RVX)

October 5, 2009

Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers

September 29, 2009

Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data

September 25, 2009

Standard & Poor's annonce des modifications aux indices canadiens S&P/TSX

September 11, 2009

Resverlogix Phase 1b/2a Study Meets Primary Endpoint

August 25, 2009

Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

May 19, 2009

Resverlogix Provides Quarterly Update

April 28, 2009

Resverlogix Closes CDN $24.25M Financing

April 15, 2009

Resverlogix Announces Subscriptions for its Equity Financing

April 6, 2009

Resverlogix Confirms a US $20 Million Equity Financing Plan

March 11, 2009

Resverlogix Board of Directors Update

November 26, 2008

RVX-208 Data Demonstrates Increase in Functional HDL Particles

November 10, 2008

RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

November 10, 2008

Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial

October 21, 2008

Resverlogix Announces Closing of Debt Redemption

October 17, 2008

Resverlogix Eliminates Sixty Percent of Remaining Debt

October 15, 2008

Resverlogix Issues a Management Statement

October 7, 2008

International Steering Committee for RVX-208 IVUS Trial Formed

October 7, 2008

ApoA-I Data Presented at European Society of Cardiology Congress

September 2, 2008

Phase 1b/2a Program Commences for RVX-208

August 25, 2008

Resverlogix Notice of Conference Call & Webcast

August 21, 2008

Jan Gray Joins Resverlogix Board of Directors

July 25, 2008

Resverlogix's Lead Drug Featured in Key Scientific Publication

July 18, 2008

Industry Leaders Select Resverlogix's RVX-208

July 9, 2008

Resverlogix to Collaborate with Cleveland Clinic

June 19, 2008

Key Primary Resverlogix Objective Obtained

June 18, 2008

/C O R R E C T I O N from Source -- Resverlogix Corp./

May 1, 2008

Dosing for RVX-208 Phase 1a Clinical Study Completed

April 22, 2008

Resverlogix Share Option Extension

April 21, 2008

Progress Report from RVX-208 Phase 1 Clinical Study

January 14, 2008

FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208

December 10, 2007

Resverlogix Honoured with World Economic Forum Technology Pioneer Award

November 29, 2007

Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting

November 5, 2007

Resverlogix is Presenting at IAS HDL Workshop

October 11, 2007

Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM

October 4, 2007

← Newer news releases

Decks

The 5 newest of 11 decks. Every deck is listed under its year.